VIVUS Inc

VIVUS — Investor Presentation (October 2013)

17 slides from VIVUS's investor presentation, Oct 15, 2013

  1. Slide 1: Innovative Therapies Novel Products

    INNOVATIVE THERAPIES NOVEL PRODUCTS OCT-2013 ©2013 VIVUS Inc. All rights reserved | www.vivus.com

  2. Slide 2: Forward Looking Statement

    FORWARD LOOKING STATEMENT This presentation contains “forward looking” statements that involve risks and uncertainties. These statements typically may be identified by the use of forward looking words or phrases such as “may,” “believe,” “expect,” “forecast,” “intend,” “anticipate,” “predict,” “shou

  3. Slide 3: Recent Highlights – 2H 2013

    RECENT HIGHLIGHTS – 2H 2013 Qsymia available in certified retail pharmacies July 1 New Board of Directors elected August 14 New CEO, Seth Fischer, announced September 3 Qsiva EU strategy update provided September 20 New Qsymia data in prediabetes/metabolic syndrome published in Diabetes Care October

  4. Slide 4: Seth H. Z. Fischer, CEO

    SETH H. Z. FISCHER, CEO Three decades of healthcare experience Pharmaceuticals & Medical Devices, Johnson & Johnson Company Group Chairman and Worldwide Franchise Chairman, Cordis Corporation (2008 to 2012) Company Group Chairman, North America Pharmaceuticals (2004 to 2007 - Ortho-McNeil Pharmaceut

  5. Slide 5: Qsymia Prescribing Information

    QSYMIA PRESCRIBING INFORMATION ©2013 VIVUS Inc. All rights reserved | www.vivus.com 4

  6. Slide 6: VIVUS Corporate Priorities

    VIVUS CORPORATE PRIORITIES 1) Expand use of Qsymia through targeted HCP and patient education 2) Find the right partner for Qsymia 3) Quickly create a pathway for approval in Europe 4) Eliminate expenses that are not essential to expanding use of Qsymia ©2013 VIVUS Inc. All rights reserved | www.viv

  7. Slide 7: Qsymia Prescriptions

    Source: VIVUS, Inc. Data on file – 04-Oct-2013; *3Q2013 is estimated QSYMIA PRESCRIPTIONS* 6 +~33%

  8. Slide 8: Qsymia Retail Roll-out Success

    QSYMIA RETAIL ROLL-OUT SUCCESS Certified Retail Pharmacy Status (14-Oct-2013) >26,000 pharmacies now certified to dispense Qsymia Chains include: A&P, Albertsons, Costco, CVS, Kmart, Kroger, Publix, Rite Aid, Safeway, Walgreens/Duane Reade, Walmart, Wegmans, Winn-Dixie, many others Prescriber and pa

  9. Slide 9: Qsymia Reimbursement Continues to Improve

    QSYMIA REIMBURSEMENT CONTINUES TO IMPROVE As of 30-Sep-2013, ~38% of U.S. Commercial Lives have access to Qsymia at Tier 3 or better YE2013 Goal: 50% 2014 Focus: Improve access & pull-through ©2013 VIVUS Inc. All rights reserved | www.vivus.com 8

  10. Slide 10: Recent Publication Reports Impact of Qsymia on Type 2 Diabetes

    RECENT PUBLICATION REPORTS IMPACT OF QSYMIA ON TYPE 2 DIABETES Publication: Diabetes Care October 8, 2013 - doi:10.2337/dc13-1518 - W. Timothy Garvey, MD, et al Title: “Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended-

  11. Slide 11: Qsymia European Strategy

    QSYMIA EUROPEAN STRATEGY Goal Satisfy FDA post-approval requirements with a single CVOT that could also support EU registration Strategy Create an early stop in CVOT so that ~two years of data could be used to support an application while the trial continues Tactics Use the new 90-day EU consultatio

  12. Slide 12: AQCLAIM Study (CVOT)

    AQCLAIM STUDY (CVOT) A Qsymia® CardiovascuLAr morbIdity and Mortality (AQCLAIM) Study in Subjects with Documented Cardiovascular Disease Primary Efficacy Endpoint: Time to 1st occurrence of nonfatal MI, nonfatal stroke or CV death Number of Subjects: ~11,000 - 16,000 Number of Sites: ~450 (North Ame

  13. Slide 13: STENDRA Prescribing Information

    STENDRA PRESCRIBING INFORMATION About STENDRA™ STENDRA is a prescription medicine used to treat erectile dysfunction (ED). STENDRA (avanafil) is licensed from Mitsubishi Tanabe Pharma Corporation. VIVUS has development and commercial rights to STENDRA for the treatment of sexual dysfunction worldwid

  14. Slide 14: STENDRA Partnership with Auxilium

    STENDRA PARTNERSHIP WITH AUXILIUM October 11, 2013 – Auxilium Pharmaceuticals, Inc. to Launch and Market STENDRA in U.S. and Canada AUXL 2012 Product Revenues: $~303 million Offices: Chesterbrook, PA Employees: 526 U.S. Sales Force: 150 Men’s Health Portfolio: Testim® (testosterone gel) for hypogona

  15. Slide 15: STENDRA Partnership with Auxilium

    STENDRA PARTNERSHIP WITH AUXILIUM Territories: U.S. & Canada VIVUS to Receive Up-front Payment Plus Milestones and Royalties Over the Term of the Agreement Total Deal Value: ~$300 million plus royalties Up-front Payment: $30 million Regulatory Milestones: $15 million (expansion of label) Sales Miles

  16. Slide 16: SPEDRA Partnership with Menarini

    SPEDRA PARTNERSHIP WITH MENARINI Menarini Territories: 40 Countries in Europe, plus Australia & New Zealand VIVUS to Receive Up-front Payment Plus Milestones and Royalties Over the Term of the Agreement Total Deal Value: ~$100 million plus royalties Up-front Payments Regulatory Milestones Launch Mil

  17. Slide 17: VIVUS Summary

    VIVUS SUMMARY Qsymia prescriptions and payor acceptance moving in the right direction Clear inflection in TRxs with retail availability Improving reimbursement Qsiva pathway in EU being finalized; CVOT refinements Avanafil monetization in Europe and U.S. Together, potentially >$95 million in cash th

Vivus — Investor Presentation (October 2013) on 6ix